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ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is a molec-
ularly heterogeneous group of malignancies with
frequent genetic abnormalities. G-quadruplex (G4)
DNA structures may facilitate this genomic insta-
bility through association with activation-induced
cytidine deaminase (AID), an antibody diversifica-
tion enzyme implicated in mutation of oncogenes
in B-cell lymphomas. Chromatin immunoprecipita-
tion sequencing analyses in this study revealed that
AID hotspots in both activated B cells and lym-
phoma cells in vitro were highly enriched for G4 el-
ements. A representative set of these targeted se-
quences was validated for characteristic, stable G4
structure formation including previously unknown
G4s in lymphoma-associated genes, CBFA2T3, SPIB,
BCL6, HLA-DRB5 and MEF2C, along with the estab-
lished BCL2 and MYC structures. Frequent genome-
wide G4 formation was also detected for the first
time in DLBCL patient-derived tissues using BG4, a
structure-specific G4 antibody. Tumors with greater
staining were more likely to have concurrent BCL2
and MYC oncogene amplification and BCL2 muta-
tions. Ninety-seven percent of the BCL2 mutations
occurred within G4 sites that overlapped with AID
binding. G4 localization at sites of mutation, and
within aggressive DLBCL tumors harboring ampli-
fied BCL2 and MYC, supports a role for G4 structures
in events that lead to a loss of genomic integrity, a
critical step in B-cell lymphomagenesis.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is an aggressive
non-Hodgkin’s lymphoma (NHL) with a higher incidence
relative to other NHL subtypes in both the United States
and Europe (1,2). While the standard immunochemother-
apy regimen involving rituximab, cyclophosphamide, dox-
orubicin, vincristine and prednisone (RCHOP) improved
outcome for patients with DLBCL, roughly 40% of patients
experience a rapid clinical progression and drug-resistant
disease (3). The failure to achieve long-term disease-free
survival is likely due to the complex genetic heterogene-
ity of DLBCL, which is highlighted by multiple molec-
ular subtypes with varying patient outcomes. For exam-
ple, the germinal center B-cell (GCB)-derived cell-of-origin
(COO) subtype is characterized by frequent mutations in
genes involved in epigenetic and germinal center (GC) re-
action regulation, while the activated B-cell (ABC)-like
subtype is associated with mutations leading to an al-
tered B-cell receptor signaling and an inferior patient out-
come (4–8). In addition, a particularly refractory subset
of DLBCL tumors consists of BCL2 and MYC translo-
cations and/or amplifications resulting in double positive
BCL2/MYC protein expression with most patients surviv-
ing <5 years due to the lethal combination of highly pro-
liferating and chemotherapy-resistant tumors (3,9–12). The
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molecular mechanism as to why the DLBCL genome is
prone to genetic deregulation is unclear, though an enzyme,
activation-induced cytidine deaminase (AID), is thought to
be a key factor (13–18).
Normally, AID-directed mutations in immunoglobulin
(Ig) genes generate the diverse antibody repertoire via
somatic hypermutation and class switch recombination
(19,20). AID induces point mutations via deaminating cy-
tosine to uracil predominantly at AGCT motifs, which most
commonly leads to dC>dT transition when left unrepaired,
but depending on how the lesion is recognized, processed
and repaired, dA>dG and dA>dC mutations can also oc-
cur (21,22). Mismatch repair often facilitates what is re-
ferred to as the second phase of somatic hypermutation
where a patch DNA synthesis process causes accumulation
of A:T substitutions (22). When the altered nucleotide oc-
curs within Ig variable regions, somatic hypermutation re-
sults and enhances antibody affinity. Lesions within Ig con-
stant switch regions produce double-strand breaks, subse-
quent recombinational deletion of the IgM constant ex-
ons and Ig class switching. Together, these processes yield
high-affinity, specific antibodies following antigen presen-
tation (21,22). Aberrant AID activity outside Ig genes,
however, is associated with mutation and rearrangements
linked to lymphoma. Previous sequencing studies in DL-
BCL revealed recurrent non-Ig genes that contain mutation
hotspots with AID hypermutation signatures (7,8,16). The
classic features of AID hotspots seen in oncogenes are sim-
ilar to those in Ig genes and are characterized by single-
stranded DNA regions near promoters, sites undergoing
active transcription and super-enhancer (SE) regions par-
ticularly those within convergent transcription (23–27). A
recent study demonstrated that AID recognizes an alter-
native DNA conformation for class switch recombination
(28), called the G-quadruplex (G4), which supports previ-
ous findings of AID interaction with guanine (G)-looped
stretches of single-stranded DNA (29,30).
The influence of DNA topology on its dynamic function
and maintaining genomic processes is becoming increas-
ingly recognized. The rapidly progressing G4 field demon-
strates their discovery in nuclear activities such as replica-
tion and transcription, and links G4 DNA with regions
of gene amplification (31–33). Our research efforts previ-
ously showed that DNA secondary structures within the
BCL2 and MYC promoter regions serve as therapeutic tar-
gets for modulating oncogene expression (34–36). G4 sec-
ondary DNA structures arise from at least four contigu-
ous runs of Gs separated by intervening loop sequences
of variable length and are frequently found in the promot-
ers of oncogenes (32,33,37). A novel antibody probe for
detecting G4 structures in DNA indicated that in some
cancer tissues G4 structures occur more frequently in ma-
lignant cell nuclei compared to their benign counterparts
(38). Together with AID recognition of G4s, these studies
strongly implicate a role for such alternative DNA struc-
tures in the loss of genomic integrity that might lead to
oncogenesis in B cells. However, the prevalence and molec-
ular associations of G4 formation within AID hotspots and
other genetic abnormalities, particularly in lymphoma, are
unknown.
Here, we sought to address whether G4s are involved in
the recruitment of AID to targeted regions within B-cell
and DLBCL genomes and can identify tumors with ge-
netic events such as mutations and amplifications. We eval-
uated the presence of G4 structures in DLBCL tissues, the
frequency of G-based structure-forming sequences within
AID-targeted genomic loci and the impact these patterns
have on the presence of genetic alterations in BCL2 and
MYC as well as patient outcome. This study provides insight
into the involvement of these highly G-rich DNA sequences
in AID mutational activity and genomic instability.
MATERIALS AND METHODS
Patient samples
A total of 277 pre-treatment DLBCL biopsy formalin-
fixed, paraffin-embedded tissues (FFPETs) from previ-
ous Leukemia/Lymphoma Molecular Profiling Project
(LLMPP) studies (5,12,39) were used in this study for dif-
ferent analyses. Overall, there were 162 male and 115 female
patients with an average age of 60 years at diagnosis (range:
14–92 years). In the AID mRNA analyses, 216 cases were
used with the COO assigned by the gene expression profiling
(GEP) algorithm (5) as 91 ABC, 100 GCB and 25 unclassi-
fied (UNC). A subset of 90 cases with available blocks for
section and scroll preparation was utilized for immunohis-
tochemical and sequencing analyses. The COO for the sub-
set cohort was assigned by GEP or the Hans algorithm (40)
for 80 cases as 38 ABC, 35 GCB, 6 UNC and 1 non-GCB.
There were 10 in-house cases without COO determination.
The unknown and non-GCB COO cases were only used in
the overall DLBCL analyses and grouped together as un-
known. These 11 cases were excluded from COO-specific
analyses. BCL2 and MYC amplification and translocation
status was obtained in our previous studies (12,39). Sections
of benign tonsil served as control tissue. The use of human
tissues and clinical data for this study was approved from
the University of Arizona Institutional Review Boards in
accordance with the Declaration of Helsinki.
Gene expression analyses
Raw cel files were downloaded from the Gene Expression
Omnibus (GEO) website (accession number GSE10846).
The cel files for the additional nine in-house cases along
with the normal B-cell and DLBCL cell lines were obtained
from the NIH LLMPP consortium. The cel files were im-
ported into Partek Genomics Suite software and subjected
to a robust multichip averaging, GC and quantile normal-
ization followed by a log2 transformation as previously de-
scribed (41).
Immunohistochemistry
FFPET slides were prepared at 4 m and stained using the
BenchMark® XT instrument (Ventana Medical Systems,
Tucson, AZ) for AID with an anti-AID antibody (ab59361,
Abcam; 1:2000 dilution). Cytoplasmic staining was consid-
ered positive and no nuclear staining was observed. Similar
staining patterns and protein identification were previously
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reported using this same antibody (42,43). For G4 detec-
tion, we adapted a manual cell-based assay with a FLAG-
tagged single-chain Fv antibody (BG4) to develop an au-
tomated colorimetric protocol on the BenchMark® XT in-
strument. Each slide was deparaffinized with a 56-min CC1
cell-conditioning regimen, incubated for 32 min at 37◦C and
detected with the OptiView DAB immunohistochemistry
(IHC) detection kit. Slides were scored for the presence of
AID or BG4 staining within a 150 cell count. Out of the 90
cases available, 74 were successfully stained for AID and 86
for BG4 scoring due to loss of tissue integrity during stain-
ing protocol or poor staining (i.e. expected positive control
cells did not stain).
Immunofluorescence
U2932 DLBCL cells were treated with 10 M pyrido-
statin (PDS) for 2 min and then washed with phosphate-
buffered saline (PBS) before seeding onto poly-L-lysine-
coated coverslips. The coverslipped cells were fixed with
3.7% paraformaldehyde for 30 min at room temperature
followed by a PBS wash and then permeabilized with cold
methanol at −20◦C for 5 min. Cells were treated with 50
g/ml RNase A for 1 h at room temperature before subject-
ing to immunofluorescence with the same antibodies used
for IHC, BG4 and AID. Secondary antibodies conjugated
to Alexa Fluor 488 (goat anti-rabbit) and Alexa Fluor 594
(goat anti-mouse) from Invitrogen at a dilution of 1:500
were applied with a counterstain of DAPI (Thermo Fisher
Scientific). Coverslips were mounted onto cover glass with
an anti-fade solution [0.02% p-phenylenediamine (Sigma,
P6001) in 90% glycerol in PBS]. Samples were visualized
and captured using a Ti-2 inverted C2+ confocal micro-
scope and AID and BG4 foci were quantified in 100–150
nuclei with ImageJ software. The resulting number of foci
in each nucleus was plotted and assumed to follow a Pois-
son distribution rather than a normal distribution. Accord-
ingly, to evaluate whether PDS had an effect on the number
of foci in each cell, we performed an exact test based on the
Poisson distribution.
BCL2 sequencing and mutational analyses
Eleven primer pairs were designed for amplification of exon
1, exon 2 and exon 3 of BCL2 using the Primer3 software
(Supplementary Table S1). Samples were prepared at 10 ng
of template DNA per PCR reaction following the Illumina
two-step PCR protocol. Multiple indexed libraries were
pooled and sequenced on the Illumina MiSeq using 150-bp
paired-end reads. The BWA-mem aligner v0.7.5a (44) was
used to align the amplicon sequencing reads against the hu-
man reference genome (hg19). Variants were detected us-
ing VarScan version 2.3.6 (45) and filtered for non-silent
coding and non-coding BCL2 mutations. Germline muta-
tions were removed based on the presence in dbSNP ver-
sion 137 (46) or having an allele frequency >75%. Poten-
tially artifactual mutations were manually inspected using
the Integrated Genome Viewer version 2.3.25 (47), flag-
ging the removal of a mutation at chr18:60985870 oc-
curring at an allele frequency of ∼10% and in 93% of
patients.
In silico analyses and evaluation of potential G4-forming se-
quence stability
We constructed a fasta file containing the genomic re-
gions of previously identified AID targeting sequences
(25,26) and performed an in silico search for potential
G4-forming sequence (PQS). The same genome versions
for mouse (mm9) and Homo sapiens (hg19) as previously
used (25,26) were downloaded from the University of
California, Santa Cruz genome browser and the mouse
B-cell SE BED file (GSE62063 aB H3K27Ac SuperEn-
hancers.bed) from the NCBI GEO. The fastaFromBed
tool, a part of the BEDTools package, created a fasta
file from the mouse mm9 genome using the genomic lo-
cations found in the GSE62063 BED file. A custom perl
script extracted the G4 sequences, number of sequences
(counts) and locations of the G4 sequence from the fasta
file. The perl script used the regular expression (regex)
function to search the fasta file for the G4 sequence pat-
tern GGGN(1–7)GGGN(1–7)GGGN(1–7)GGG, using the es-
tablished PQS algorithm where N can be any nucleotide
(37). Likewise, to evaluate the non-SE AID target re-
gions in mouse ABCs and the human Burkitt’s lymphoma
cell line AID targets, separate BED files specific for the
AID target mm9 and the hg19 loci, respectively, were cre-
ated and subjected to the same custom perl script. Se-
quences were selected using a positive lookahead assertion
(i.e. /? = pattern/gi). All possible candidates were selected
that matched the regex pattern query, enabling overlap of
matched patterns.
To assess the quadruplex propensity score for the identi-
fied PQSs, we performed G4 motif identification in hg19 us-
ing the G4Hunter algorithm (48) with a score >1 and win-
dow size of 25. The G4Hscore of each PQS was calculated,
and the G4Hscore represents the propensity of a sequence
to form a G4. The maximum score of G4Hscore was as-
signed to each SE. A Wilcoxon rank-sum test was used to
determine a significant difference between the G4Hscore of
PQS within SE loci targeted by AID and those loci not tar-
geted by AID.
Chromatin immunoprecipitation sequencing
U2932 DLBCL cells obtained from the American Type Cul-
ture Collection were grown in RPMI 1640 medium (Corn-
ing) supplemented with 10% fetal bovine serum (Atlanta Bi-
ologicals) and 1% Pen/Strep (Gibco). Chromatin immuno-
precipitation (ChIP) was carried out using Peirce Mag-
netic ChIP kit according to the manufacturer’s instruc-
tions (Thermo Scientific). Exponentially growing cells were
cross-linked with 1% formaldehyde and then quenched with
glycine for 5 min at room temperature followed by lysis and
MNase digestion. Samples were sonicated for 60 min using
the Bioruptor (Diagenode). For each immunoprecipitation
reaction, 4 × 106 chromatin cell equivalents were incubated
overnight with either an AID antibody (Abcam, ab59361)
or a rabbit IgG negative control antibody, subjected to pro-
tein A/G magnetic bead binding, IP elution and DNA re-
covery. The ChIP DNA was used to generate ChIP se-
quencing (ChIP-seq) libraries with the ChIP-seq sample
preparation kit (Illumina) for sequencing at the Arkansas
Children’s Research Institute Genomics Core. The human
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genome hg19 version was used for mapping AID ChIP-seq
reads and PQS prediction.
AID ChIP data analysis
Raw sequence reads were preprocessed to ensure that
only the high-quality reads will be used for further
bioinformatics analysis; adapter trimming and quality
filtering were performed using fastp software v0.19.5
with default parameters (49). The resulting high-quality
reads were then aligned to the human genome version
hg19, using BWA-MEM v0.7.17 with ‘-M’ as parame-
ter (50). The PCR duplicate reads were then removed
using MarkDuplicates from Picards package v2.9.2
(http://broadinstitute.github.io/picard) with default param-
eter. The uniquely mapped reads were filtered (mapping
quality score MAPQ ≥30), sorted and converted to BAM
files using SAMtools (http://samtools.sourceforge.net/).
The BAM files were subjected to subsequent processing
with model-based analysis for ChIP-seq (MACS2 v2.1.1,
https://pypi.python.org/pypi/MACS2). Enriched peak
regions of the genome were identified by comparing the
AID antibody and a rabbit IgG (a mock pull-down)
sample to whole cell extract samples using callpeak from
MACS2 with modified parameters ‘-f BAMPE –broad
–broad-cutoff 0.1’. The AID enriched peaks were filtered
out if they overlap with the mock pull-down peaks and
the blacklist (ENCODE blacklisted regions), which is
combined from a consensus list empirically defined by
the Encyclopedia of DNA Elements (ENCODE) con-
sortium, available at http://hgdownload.cse.ucsc.edu/
goldenPath/hg19/encodeDCC/wgEncodeMapability/
wgEncodeDacMapabilityConsensusExcludable.bed.gz.
Data are available from the GEO website (accession
number GSE146695).
Random permutation tests for assessing the association of
AID peaks with PQS and activated mouse B-cell SEs, and
BG4 peaks with AID-targeted loci
The activated mouse B-cell SE BED files were converted to
the human genome (hg19) coordinates using CrossMap (51)
with the mm9 to hg19 liftover chain file from UCSC. The
permutation tests were used to assess the association of AID
peaks with PQS and activated mouse B-cell SEs. We gener-
ated 60 random genomic location sets (control sets), pre-
serving the number per chromosome and size of the orig-
inal AID peaks. The shuffleBed in the BEDTools v2.25
(52) was used to randomly permute the genomic locations
of AID peaks with parameters (-noOverlapping -chrom).
Number of each control set containing PQS and activated
mouse B-cell SEs was calculated and used as a null distri-
bution. The number of the observed AID peaks containing
PQS and activated mouse B-cell SEs was then compared
to that from control sets and one-sample Student’s t-test
was performed. The BEDTools Fisher’s test function was
used to determine the number of observed AID peaks that
overlapped with BG4 peaks from our previous BG4 ChIP
(GSE99205).
Circular dichroism
Circular dichroism (CD) analyses were conducted on a
Jasco-1100 spectropolarimeter (Jasco, Easton, MD) as pre-
viously described (35). The G4-forming oligonucleotides
were prepared at a 5 M strand concentration in a 10 mM
Tris–HCl buffer (pH 7.4) with various KCl concentrations
(0–100 mM). Melting curves were recorded at the wave-
length of the maximum spectral molar ellipticity over 4–
95◦C and then plotted against temperatures for Tm determi-
nation (35). Tm values were calculated within ±1◦C error us-
ing the log(inhibitor) versus response nonlinear regression
fit on Prism software.
Survival analyses
Cut points for high and low expression of AID mRNA and
protein, and BG4 staining were determined by the Youden
index via a receiver operating characteristic (ROC) curve
analysis using MedCalc software (53). Overall survival (OS)
and progression-free survival (PFS) were defined as the time
from date of diagnosis to the date of death or last follow-up
and as the time from date of diagnosis to the date of DLBCL
progression or death due to any cause, respectively. OS and
PFS curves were estimated using the Kaplan–Meier method
and plotted with GraphPad Prism software. Significant dif-
ferences (P < 0.05) were assessed using the log-rank test and
the Cox proportional hazards model was applied to deter-
mine independence from other covariates.
Statistical analysis
For mRNA expression, differences were assessed by a
multiple-test corrected one-way ANOVA using the Ben-
jamini and Hochberg false discovery rate with the Partek
Genomics Suite software v7. All other statistical analyses
were performed with GraphPad Prism software v6 and v7.
Significance (P < 0.05) was evaluated for two-group com-
parisons using a two-tailed Student’s t-test unless multiple
testing occurred and then the Šı́dák–Bonferroni correction
was used to adjust the P-value. Fisher’s exact test was ap-
plied to determine significant differences in the genomic loci
with PQS present or absent. The Mann–Whitney test com-
pared PQS per locus within AID targets according to over-
lap with SE regions and BCL2 mutation counts between
ABC-DLBCL and GCB-DLBCL samples. Data are repre-
sented as either mean ± standard error of the mean (SEM)
or median ± minimum and maximum values unless other-
wise stated.
RESULTS
G4 formation is detectable in DLBCL nuclei, occurs more
frequently in ABC-DLBCL and tends to correlate with a
lower helicase expression
Given the extensive occurrence of G4 sequences within
the genome (32,33) and detection of G4 structure forma-
tion in cancer tissues (38), we sought to determine the fre-
quency of G4 formation in DLBCL tissues. To visualize
formed G4 complexes within DLBCL FFPET, we adapted
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the single-chain Fv BG4 antibody (38,54) to develop a semi-
automated colorimetric IHC protocol. A non-malignant
tonsil biopsy was used for optimization and we observed
BG4-positive staining of B cells within the GC, mantle zone
(MZ) and interfollicular regions (Figure 1A). The majority
of DLBCL tumors displayed positive malignant cell nuclei
indicating the frequent presence of formed G4 structures
with intense staining observed in mitotic nuclei (Figure 1A,
inset). G4 formation was detected in 85% (73/86) of the DL-
BCL FFPET (Supplementary Figure S1). The median per-
cent BG4-positive malignant cells within a given tumor was
50%, and using ≥50% as a cutoff, there was a strong trend
for a higher incidence of G4 formation in ABC-DLBCL
in comparison to GCB-DLBCL (21/37, 57% versus 11/34,
32%; P = 0.06). ABC-DLBCL cases also tended to exhibit
more BG4-positive malignant cells on average, although the
difference was not significant (Figure 1B).
We next investigated whether the mRNA expression of
helicases known to unwind G4 structures, including PIF1
(55), RECQL5 (56), XPB/D (57) and ATRX (58), was lower
in ABC-DLBCL and potentially accounted for the differ-
ence in G4 formation between the two DLBCL COO sub-
types. Of the 86 cases with BG4 staining, 46 had available
gene expression data; however, there were no significant dif-
ferences in expression of the five helicases between the ABC-
DLBCL and GCB-DLBCL (Supplementary Table S1). De-
spite an overall tendency for ABC-DLBCL to display more
G4 formation, over half of the GCB-DLBCL and all of the
UNC-DLBCL tissues consisted of detectable G4 staining.
When the tissues were examined for helicase expression ac-
cording to high G4 positivity (≥50%) irrespective of DL-
BCL subtype, tumors with low XPD mRNA levels were
more likely to have G4 formation compared to cases with
high XPD (15/23, 65% versus 8/23, 35%; P = 0.08; Figure
1C).
DLBCL with concurrent BCL2/MYC gene amplification has
increased G4 formation
G4 formation, if left unresolved by helicases, may lead to
DNA replication errors resulting in increased genome in-
stability and gene amplification. Therefore, it is notable
that elevated G4 formation was observed in DLBCL cases
with dual BCL2/MYC amplification and with MYC am-
plification only (Figure 1D). BG4 staining was not signifi-
cantly different in DLBCL tumors that consisted of either
a BCL2 or MYC translocation compared to tissues nega-
tive for these translocations (Figure 1E). Amplification and
translocation status was determined in previous publica-
tions (12,39). These findings suggest that G4 formation in
DLBCL correlates with aberrant and dramatic amplifica-
tion of these two critical oncogenes.
Genomic loci targeted by AID are highly enriched for G4 for-
mation whether within or outside SE regions
Due to the potential for G4 structure involvement in mech-
anisms of genomic instability important in lymphoma biol-
ogy such as somatic hypermutations and class switch recom-
bination (28–30), we investigated whether sequences encod-
ing G4s uniquely define AID targets relative to non-AID-
targeted areas of the genome. First, we interrogated 1003
SEs previously identified in activated mouse embryo B cells
(25), of which 167 distinct SE regions were targeted by AID.
We investigated co-incidence between PQSs, SEs and AID-
targeted regions. Considering all 1003 SEs, the 167 AID-
targeted SEs consisted of a significantly higher average of
PQSs per locus (28 versus 22; P < 0.004) and AID-targeted
SEs are two times more likely to harbor at least 28 PQSs
compared to the non-AID-targeted SEs (Figure 2A and
Supplementary Table S2A). Of note, G4 sequences were de-
tected in non-AID SE regions at a range of 0–121 PQSs
per locus indicating that G4-forming sequences may be a
common feature to SE regions. In the same mouse B cells,
an additional 69 AID targets were identified, 6 SEs con-
tained 2–3 targeted loci and 62 AID targets fell outside SE
regions completely. We then assessed all 236 AID-targeted
loci according to SE overlap and found that targets within
SEs had a significantly higher number of PQSs per locus
than targets outside an SE region (Figure 2B and Supple-
mentary Table S2B). We next evaluated the 54 AID targets
found in a parallel study using the Ramos Burkitt’s lym-
phoma cell line. Twenty-eight of these AID targets were as-
sociated with SEs, 42 with areas of convergent transcrip-
tion and 10 were not associated with either SE or conver-
gent transcription genomic regions (23). Similarly, we ob-
served PQSs present regardless of genomic overlap of SE
and/or convergent transcription with the highest frequency
of PQSs in SE-associated AID targets (Supplementary Ta-
ble S2C).
We then performed AID ChIP-seq to determine whether
the genomic regions targeted by AID in DLBCL are
also enriched for PQSs using the well-characterized U2932
ABC-DLBCL cell line. AID ChIP-seq peaks mapped to
4573 loci and overlapped with 638 PQSs. Since PQSs are
found throughout the genome and in close proximity to
transcription start sites similar to AID-targeted elements
(25), we aimed to control for this abundance and further
confirm the identified PQSs are enriched within AID tar-
gets. We therefore integrated the activated mouse B-cell
SEs, from mm9 to hg19, with our identified DLBCL AID-
targeted regions (4573 AID peaks) and performed the per-
mutation tests of the association of the AID peaks with the
two sets of PQSs and activated mouse B-cell SEs (see the
‘Materials and Methods’ section). We observed that the in-
tersection of AID peaks with PQSs and SEs is significantly
higher than expected by chance in all cases of comparisons
and supports that the number of AID peaks sharing PQSs
and/or SEs is not a random event (Figure 2C). Consistent
with this strong association, analysis of genome-wide G4 se-
quences identified from a previous BG4 ChIP (59) demon-
strated these PQSs were highly enriched for AID-targeted
loci. We found that 252 peaks of AID-targeted loci over-
lapped with BG4 ChIP-seq peaks more often than expected
by chance (odds ratio = 11.4; P = 1.16e−174; Supplemen-
tary Table S2D).
Next, we first validated ChIP-seq-based AID peaks with
known AID targets, MYC and the IgH locus (25,26,30),
and found overlapping of our signal to the previously re-
ported AID peaks and PQSs (Figure 2D and Supplemen-
tary Figure S2). Interestingly, BCL2 is a known target of
AID (16,17), but was not identified in the earlier studies
as an AID-targeted locus (25,26). Here, for the first time,
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Figure 1. BG4 staining indicates G4 formation is frequent in DLBCL tissues, particularly in non-GCB subtypes, and correlates with BCL2 and MYC
amplification. (A) Representative BG4 staining in a non-malignant tonsil biopsy with positive staining within a normal GC and the MZ, and DLBCL
tissues that stained negative, low or highly positive with intense staining in mitotic nuclei (inset). Original magnification is ×1000. Scale bar represents
10 m. (B) Percent BG4-positive DLBCL cells in DLBCL tissues (n = 77) according to COO. (C) Percent BG4-positive DLBCL cells according to low
or high mRNA of the given DNA helicase. Percent DLBCL cells positive for BG4 staining in tumors with BCL2 and/or MYC amplification (D) or
translocation (E). Box and whisker plot: line is the median; error bars are the minimum and maximum. *Adjusted P < 0.05 as determined by a two-tailed
t-test with Šı́dák’s multiple test correction; ns, not significant.
we detected AID peaks primarily in exon 1 of BCL2 (Fig-
ure 2E), most of which aligned with a PQS known to form
stable G4s (60). In addition to these genes, we showed the
overlapping of AID peaks and PQSs in two other genes,
CBFA2T3 and SPIB (Figure 2F and G). One of the top sig-
nificant AID ChIP-seq signal clusters mapped to CBFA2T3
(MTG16), a gene translocated in myeloid malignancies, and
associated with a high density of PQSs. We found multi-
ple PQSs overlapping with AID peaks in SPIB, an onco-
gene essential for ABC-DLBCL cell survival (6) that was
also identified as an AID target in mouse ABCs (25). In
agreement with SEs as preferred AID peaks, we also pulled
down gene loci that overlapped with known SE regions, as
observed with IL21R (Figure 2H), a gene that undergoes
DNA double-strand breaks in the presence of AID (25).
To assess the stability of the PQS on a more global scale,
we applied the quadruplex propensity score or G4Hscore
(48). The G4Hscore accounts for G-richness, G-skewness
and the presence of G-blocks in a given sequence to indicate
propensity to form. A higher G4Hscore favors highly stable
G4 motifs. The PQSs in SE regions targeted by AID show
significantly higher G4Hscores than those not targeted by
AID (Figure 2I).
To confirm that PQSs within the previously identified
AID targets and the newly detected sequences in the AID
ChIP-seq can form G4s, we selected five G4 sequences from
the Burkitt’s human lymphoma cell line and one from each
of the SPIB and CBFA2T3 loci for biophysical analysis
(Supplementary Table S3). The selected genes have rele-
vance to lymphoma biology (BCL6, HLA-DRB5, MYC,
MEF2C) or a canonical AID target (IgG Sμ) and repre-
sent different genomic overlap (i.e. SE, ConvT or none).
The MYC sequence is an extended version of the well-
characterized and inherently stable G4 structure (61) and
provides a control to compare the structure formation and
stability of the newly identified PQSs. All of the PQSs
demonstrated the ability to form intramolecular G4 struc-
tures with the characteristic positive maxima around 262–
266 nm and a negative maximum at 240 nm using CD
spectral analysis (Figure 3A) that exhibited K+-dependent
structure formation (Supplementary Figure S3A) and high
thermal stability with melting temperatures ranging from
66 to 95◦C (Figure 3B, Supplementary Figure S3B and
Supplementary Table S3). With AID ChIP-seq identifica-
tion of BCL2, we also included the well-characterized G4
sequence in the CD analyses as an additional control for
G4 formation, particularly because the BCL2 G4 forms a
mixed parallel–anti-parallel structure and provides a dif-
ferent CD spectral signature from the MYC parallel G4
conformation (60,61). The secondary peak at 290 nm ob-


















































































































Figure 2. AID targeting loci are enriched for G4-forming sequences. (A) Comparison of the percentage of SE regions previously detected in activated
mouse B cells (25) that contain <28 PQSs (white bars) or ≥28 (black bars) according to whether the SE region contained an AID target. ***P < 0.001 as
determined by Fisher’s exact test. (B) The mean PQSs per AID-targeted locus according to overlap with an SE region. ***P < 0.001 as determined by a
two-tailed Mann–Whitney test. (C) UpSet chart generated using UpSetR package shows the intersection of AID peaks detected in this study with PQS
and the activated mouse B-cell SEs, which were lifted over from mm9 to hg19. The observed number of AID peaks shared between PQSs and/or SEs is
indicated in the top bar chart (black bars) corresponding to the solid points below the bar chart and each column represents shared AID peaks between
the PQS and SEs (linked dots). The gray bars represent the mean of intersection of random shuffling AID peaks (n = 60) with PQSs and SEs. The vertical
bar plot reports the intersection of either PQSs or SEs. Data represent mean ± standard deviation. ****P < 1e−57 as determined by a one-sample t-test.
(D–H) UCSC genome annotations of stacked tracks beneath genome coordinate positions for each corresponding gene. PQS feature is overlaid on gene
track. For gene tracks, solid black blocks connected by horizontal lines representing introns represent coding exons. The 5′ and 3′ UTRs are displayed as
thinner blocks on the leading and trailing ends of the aligning regions. Arrowheads on the connecting intron lines indicate the direction of transcription.
AID ChIP-seq peak detected in this study (red blocks) overlaps with previously known AID binding site (30) in MYC (D) and PQS located around the
exon 1 of BCL2 (E). CBFA2T3 contained enriched AID ChIP binding sites and PQS compared to control reads (F). AID ChIP-seq peak overlapped to
multiple PQSs in SPIB (G). AID ChIP-seq peak, PQS and SE were located upstream of IL21R (H). (I) Box plot representing the G4Hscore distribution
in SE loci without and with AID-targeted regions. ***P = 4.88e−10 as determined by the Wilcoxon rank-sum test.
served for the IgG Sμ is similar to BCL2 and indicates
a mixed anti-parallel–parallel strand orientation (Figure
3A). As further support for G4 formation in PQSs that
overlap with AID-targeted regions, the selected SPIB and
CBFA2T3 PQSs exhibit K+-dependent structure formation
and thermal stability (Figure 3C and D, and Supplementary
Figure S4).
AID co-localizes with G4 structure formation within DLBCL
cell nuclei
In demonstrating a significant enrichment of both G4-
forming sequences within AID-targeted loci and conversely
AID-targeted loci within BG4 ChIP-sequenced genomic
sites, we then assessed co-localization of AID with BG4
in DLBCL cell nuclei. First, we performed co-staining im-
8 NAR Cancer, 2020, Vol. 2, No. 4
























































































Figure 3. PQSs in AID-targeted and SE regions form stable G4 structures. (A) CD spectra of PQSs found within AID-targeted regions previously identified
(25). The BCL2 sequence (blue) was included as a positive control for G4 formation. (B) Corresponding melt curves from the PQSs in (A). (C) CD spectra
of selected PQSs found within AID ChIP binding sites in SPIB and CBFA2T3 and the corresponding melt curves (D). All oligomers were prepared in 100
mM KCl–Tris buffer. CD spectra and melt curves are representative of three independent experiments. Sequences are provided for each oligonucleotide.
munofluorescence to detect AID and BG4 in untreated
U2932 DLBCL cells (Figure 4A, top panel). As expected
based on the IHC and previous literature (42,43), the bulk
of AID resides in the cytoplasm with some AID foci ob-
served in the nucleus. Out of 100–150 individual nuclei,
1.2 AID foci were detected on average per nucleus (range:
0–8; Figure 4B). While a few discrete BG4 foci appeared
in the cytoplasm, the majority of BG4 was located within
the nucleus at an average of 7.7 foci per nucleus (range:
0–28; Figure 4A and C). When the images were merged,
AID and BG4 foci were frequently found in close proxim-
ity within the nucleus and sometimes within the cytoplasm
(Figure 4A, top panel). To address whether an increased
G4 formation would recruit additional AID into the nu-
cleus with co-localization to BG4 foci, we then treated the
U2932 cells with PDS, a known G4 stabilizer (54). Treat-
ment with PDS led to a significant increase in nuclear AID
foci (mean: 1.9; range: 0–17; Figure 4B) and, to a greater
extent, an increase in BG4 foci (mean: 9.9; range: 0–38;
Figure 4C). The enhanced AID and BG4 nuclear foci re-
sulted in notable co-localization that was evident not only
by a close proximity of the AID and BG4 foci, but also as
yellow, overlapping signals in the merged images (Figure
4C, bottom panel). The AID–BG4 co-localization, partic-
ularly after G4 stabilization, supports G4 formation within
DLBCL cells and provides a nuclear environment for AID
targeting.
BCL2 mutations overlap with both AID binding sites and ar-
eas of G4 sequences
A subset of the DLBCL tissues (n = 77) was sequenced for
BCL2 mutations to explore a potential relationship between
AID targets, G4s and mutations. Consistent with the previ-
ous literature (7), this analysis revealed a high number of
recurrent BCL2 mutations (Figure 5A and Supplementary
Table S4) in 58% of tumors (45/77) with a higher frequency
in GCB-DLBCL relative to ABC-DLBCL (Figure 5B). The
BCL2 mutations found in all 45 tumors mapped to two re-
gions, exon 1 and exon 3, and aligned with the AID ChIP
signals (Figure 5C). A high prevalence of mutations (229
mutations) was located in exon 1 and overlapped with AID-
targeted regions and PQSs, including with the well-known
G4 structure (60), while only 7 mutations were seen in exon
3 and did not overlap with an AID binding site or a PQS
suggesting G4 involvement with AID-induced mutagenesis
(Figure 5C).
High AID mRNA and BG4 staining are associated with worse
PFS
The inferior survival of patients with the ABC COO of
DLBCL is well established (5). With our observation that
G4 formation is more frequent in ABC-DLBCL together
with the previous correlation with higher AID mRNA ex-
pression (5) in this DLBCL COO, we investigated whether
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Figure 4. AID localizes to G4s in DLBCL cell nuclei. (A) Immunofluorescence for AID and BG4 in DLBCL cells without (top panel) and with (bottom
panel) PDS treatment (10 M for 2 min). Discrete AID (green) and BG4 (red) were observed in the nucleus. Nuclei were counterstained with DAPI (blue).
Yellow arrowheads indicate co-localization. Scale bars represent 20 m. (B) Quantification of AID foci number per nucleus in cells without and with PDS
treatment. (C) Quantification of BG4 foci number per nucleus without and with PDS treatment. One hundred to one hundred fifty nuclei were counted
and the SEM was calculated from three independent experiments. ***P < 0.001 as determined by a Poisson exact test.
G4 formation and/or AID mRNA expression can strat-
ify patients according to poor outcome following RCHOP
treatment. The investigated cases belong to the larger co-
hort from the Lenz study (5) and we confirmed that the
level of AID mRNA was significantly elevated by 3.5-fold
in the ABC-DLBCL relative to the GCB-DLBCL cases in
the RCHOP cohort (Supplementary Figure S5A). We also
determined whether the increased AID expression in ABC-
DLBCL was seen at the protein level using IHC in a subset
of these DLBCL cases (n = 36) along with the additional
cases used in this study (n = 38). A benign tonsil sample
was used as a control (Supplementary Figure S5B). Repre-
sentative negative, low and high AID staining in DLBCL
tissues is provided in Supplementary Figure S5C. Of note,
AID staining was primarily cytoplasmic, which is in agree-
ment with previous and recent studies, along with frequent
interstitial staining (14,18).
When AID protein expression was evaluated according
to COO, there was no significant difference in AID protein
expression with ABC-DLBCL tumors exhibiting an average
64% AID-positive cells compared to 58% in GCB-DLBCL
and 71% in UNC-DLBCL (Supplementary Figure S5D).
We then plotted AID mRNA levels against protein expres-
sion from the 36 matched samples and did not see a correla-
tion (Supplementary Figure S5E). Samples with discordant
AID mRNA–protein expression, where high mRNA levels
were associated with low protein expression, were predomi-
nantly ABC-DLBCL cases suggestive that AID may be dif-
ferentially regulated post-transcriptionally in some ABC-
DLBCL tumors (Supplementary Figure S5E, pink circles).
We then analyzed each of the variables, AID mRNA,
AID IHC and BG4 IHC, independently and observed only
high AID mRNA levels identified DLBCL patients with
worse OS and PFS, which maintained a trend toward sig-
nificance with DLBCL subtype as a covariate for PFS
only (Figure 6A). The lack of association of AID pro-
tein levels with patient outcome is possibly due to post-
transcriptional/translational modifications that result in no
correlation between mRNA and protein levels (Supplemen-
tary Figure S5E). Although the correlation did not achieve
statistical significance, there is a clear separation in the sur-
vival curves that lends a slight tendency for patients with
higher BG4 staining DLBCL tumors to have a poor OS
(Figure 6A). In 17 cases, 10 ABC-DLBCL, 6 GCB-DLBCL
and 1 UNC-DLBCL, all three parameters were available for
analysis. The Cox proportional hazards regression model
demonstrated that both AID protein and G4 formation sig-
nificantly correlated with inferior patient survival (Figure
6B) indicating elevated AID expression and G4 formation
may confer poor response to current therapy.
DISCUSSION
Several lines of evidence demonstrate a role for G4 for-
mation in facilitating genomic instability, as G4 sequences
are often located at DNA breakpoints and sites of ge-
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Figure 5. BCL2 mutations in DLBCL patient samples overlap with both AID binding sites and areas of G4 sequences. (A) BCL2 mutational profile in
DLBCL. Frequency of SNPs found in the BCL2 oncogene from 45/77 DLBCL cases using a >75% frequency filter. (B) Violin plot showing the number
of mutations in BCL2 for all ABC (n = 34) and GCB cases (n = 35). Median shown as a line with the upper 95% confidence interval (CI) and the black
circles above the CI are outliers. *P < 0.05 as determined by a two-tailed Mann–Whitney test. (C) The 45 DLBCL tumors with detectable BCL2 mutations
mapped to exon 1 and exon 3. The majority of mutations (229) are located within exon 1 and overlapped with AID peaks from the ChIP-seq (red bars) and
PQS (pink bars). There were seven mutations detected in exon 3 that did not overlap with AID signals. Individual mutations are shown for each sample in
the expanded panels as blue hash marks.
nomic amplification in cancer. Additionally, defects in G4-
resolving helicases, as observed in diseases such as Bloom’s
and Werner’s syndromes, result in susceptibility for can-
cer development (32,62–64). For the first time, we demon-
strate a high frequency of G4 formation within DLBCL and
that this phenomenon associates with concurrent gene am-
plification of two highly genetically altered and prognosti-
cally important oncogenes in DLBCL, BCL2 and MYC,
as well as MYC amplification alone. This correlation sup-
ports previous work showing prominent G4 formation at
sites of genomic amplification (33) and a recent study map-
ping G4s specifically to amplified regions that character-
ize certain breast cancer subtypes (65). The loss of genetic
integrity through translocations, amplifications and muta-
tions in these important oncogenes contributes to the poor
therapeutic response of a significant portion of DLBCL pa-
tients (3). This association with patient outcome is becom-
ing increasingly evident with the recent comprehensive stud-
ies identifying distinct molecular subtypes of DLBCL ac-
cording to genetic lesions (66,67). The mechanism behind
these genetic alterations is not well understood, although
the enzyme AID is recognized as a key factor (18). We con-
firm that AID is frequently expressed within DLBCL tissues
with higher mRNA levels in ABC-DLBCL. Patients with
high-expressing AID DLBCL tumors experience poor sur-
vival and disease progression suggesting elevated AID con-
fers an aggressive phenotype.
We then investigated the co-incidence of G4-forming se-
quences at genomic sites of AID targeting, and consistent
with both AID and G4 involvement in genomic aberrations,
we found that G4 motifs with potential to form secondary
DNA structures are enriched within these regions. PQSs
were a common feature of AID targets regardless of their
association with other known AID preferential genomic en-
vironments of convergent transcription and SEs. A strik-
ing correlation occurred with BCL2, the most heavily mu-
tated oncogene in DLBCL (68), where the alignment of
AID peaks coincided with the majority of mutations iden-
tified in patient samples and PQSs, whereas loci with no ob-
served AID–PQS overlap showed a substantially lower mu-
tation rate. While the propensity of PQSs in all of the previ-
ously identified mouse B-cell AID-targeted SEs and many
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Figure 6. DLBCL OS and PFS according to AID expression and BG4 staining. (A) Kaplan–Meier curves of OS (top) and PFS (bottom) of DLBCL
patients who received RCHOP treatment according to low or high AID mRNA, AID protein or BG4 staining. Cut points were determined using the
Youden index derived from ROC curves: AID mRNA, OS > 9.95 and PFS > 10.94 log2 transformed; AID protein, OS > 5% and PFS > 30% positive
staining cells; BG4 staining, OS > 61% and PFS > 0%. (B) Plot of the Cox proportional hazards model for 17 matched cases with data for all three
variables where mean expression of the covariates is used in relation to survival probability. Corresponding coefficients are shown in the table. P-values
were obtained from the log-rank test and the Cox proportional hazards multivariate analysis where DLBCL COO was a covariate.
of the non-AID-targeted SEs indicates G4 structures may
also be involved in SE biology, the significantly higher den-
sity of these motifs within AID targets suggests an involve-
ment in AID recruitment to non-IgG loci. The incidence of
G4-forming sequences in SEs is not altogether unexpected
considering their association with enhanced chromatin ac-
cessibility, topological complexity and transcription activ-
ity (25), which are features conducive for G4 formation (33).
We also observed this trend in the DLBCL cells further
validating the previous studies; however, we were also able
to detect additional AID-targeted genes, including BCL2,
which had previously been inferred as targets for AID re-
cruitment but never demonstrated. The dense G4 landscape
within AID-targeted regions resembles that of its canoni-
cal target Ig sequences (28,69). Although the majority of
AID-targeted regions were associated with PQSs, a small
percentage did not appear to contain these G4 motifs. The
PQS algorithm used to survey the AID targets did not de-
tect non-canonical G4 DNA, which was recently recognized
to function in minisatellite genomic instability of Saccha-
romyces cerevisiae (70). Thus, our analysis may underesti-
mate the incidence of G4 DNA in AID targets. Further-
more, we did not consider upstream or downstream G4 mo-
tifs to the AID-targeted region or the density of the AGCT
consensus AID targeting sequence. Another important fea-
ture for AID targeting is genome accessibility, and given
that G4 formation most likely alters chromatin architecture,
evaluating changes in chromatin accessibility in cells with
high BG4 staining and AID co-localization will provide ad-
ditional insight into the mechanisms of AID targeting. With
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these limitations to the current study, we cannot exclude
that atypical G4 structures, the density of AGCT sites in
AID-targeted regions or chromatin architecture plays a role
in AID recruitment.
In direct support of the overlapping AID ChIP-seq peaks
and identified PQSs, we show co-localization of AID with
the G4-detecting probe BG4 within DBCL cell nuclei that
was subsequently more pronounced after increasing G4 for-
mation. While the precise mechanism for AID interaction
with G4 structures requires further study, this finding fur-
ther supports a model for G4 structure recruitment of AID
to targeted loci. Since G4 structures most likely produce a
looped-out single strand on the complementary cytosine-
rich sequence (71), it is feasible that G4 formation creates a
nuclear environment conductive for AID binding to its cy-
tosine substrate on the opposite strand. Likewise, when the
AID-targeted cytosine is contained within or in close prox-
imity to the G-rich sequence itself (28,69), formation of the
G4 structure may serve as a scaffold to enable accessibil-
ity of this cytosine within the G4 loop or capping structure.
With the importance of R loops in AID biology (72) and the
known interplay of G4s and these RNA structures during
nuclear events, G4–R loop interactions may also contribute
to the mechanism behind AID targeting (27,73).
As one of the few studies to date linking G4 forma-
tion across patient samples to genomic abnormalities and
clinical outcome, our work greatly advances this field and
demonstrates BG4 as a novel tool to directly measure G4
DNA within lymphoma tissue with potential for G4 stain-
ing to serve as a biomarker, especially given the recent find-
ings that a particularly aggressive, lethal subset of DLBCL
(MCD subtype) has frequent amplification of SPIB (66),
which we show here consists of a substantial number of
PQSs with at least one confirmed to form a stable G4. Ad-
ditionally, coupling the detection of G4 formation with the
use of emerging small molecules that recognize and regulate
G4s in several different cancer types (29) has the potential
to inform on translational efforts. Using this new methodol-
ogy, we can address the biological and clinical significance
of these structures in contributing to the genomic instabil-
ity and aggressiveness in DLBCL with application to inves-
tigate other malignancies.
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